Association of Interferon Alpha Receptor 1 with sustained virological response in hepatitis C and B co-infected patients

J Pak Med Assoc. 2017 Jul;67(7):980-985.

Abstract

Objective: To determine the association of interferon alpha receptor-1 with success rate of interferon therapy in patients co-infected with hepatitis C virus and hepatitis B virus.

Methods: The study was conducted at the Army Medical College, Rawalpindi, Pakistan, from December 2013 to November 2014, and comprised patients with hepatitis C and hepatitis B co-infection. The patients were treated with pegylated-interferon-2b plus ribavirin therapy for six months. With respect to interferon therapy, patients with undetectable hepatitis C virus-ribonucleic acid along with normal alanine aminotransferase were considered responders and patients with detectable hepatitis C virus-ribonucleic acid at week 48 were considered as non-responders. SPSS 20 was used for data analysis.

Results: Of the 86 patients, there were 50(58%) males and 36(42%) females. The presence of high pre-treatment interferon alpha receptors 1-messenger ribonucleic acid in peripheral blood mononuclear cells was significantly associated with sustained virological response (85.7% vs. 64.7%, P = 0.031). Multiple regression analysis showed that females (p < 0.001), lower hepatitis C virus-ribonucleic acid levels (p < 0.001) and lower hepatitis B virus-deoxyribonucleic acid levels (p < 0.001) were associated with expression level of interferon alpha receptors 1 in the co-infected patients.

Conclusions: Interferon alpha receptors 1-messenger ribonucleic acid may be useful for predicting response to interferon plus ribavirin therapy in hepatitis C virus/ hepatitis B virus co-infected patients who were females with lower hepatitis C virus-ribonucleic acid and hepatitis B virus-deoxyribonucleic acid levels.

Keywords: IFNAR1, Peg-Interferon therapy, Co-infection, Hepatitis C virus, Hepatitis B virus, Polymerase chain reaction, Peripheral blood mononuclear cells..

MeSH terms

  • Adult
  • Antiviral Agents / therapeutic use*
  • Coinfection
  • Cross-Sectional Studies
  • Female
  • Hepatitis B, Chronic / complications*
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / complications
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon alpha-2 / therapeutic use*
  • Interferon-alpha / therapeutic use*
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Middle Aged
  • Polyethylene Glycols / therapeutic use*
  • Prognosis
  • RNA, Messenger / metabolism*
  • RNA, Viral / blood
  • Receptor, Interferon alpha-beta / genetics*
  • Receptor, Interferon alpha-beta / metabolism
  • Recombinant Proteins / therapeutic use
  • Ribavirin / therapeutic use*
  • Sustained Virologic Response

Substances

  • Antiviral Agents
  • IFNAR1 protein, human
  • Interferon alpha-2
  • Interferon-alpha
  • RNA, Messenger
  • RNA, Viral
  • Recombinant Proteins
  • Receptor, Interferon alpha-beta
  • Polyethylene Glycols
  • Ribavirin
  • peginterferon alfa-2b